Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

5 results about "Docetaxel-PNP" patented technology

A polymeric nanoparticle (PNP) formulation containing the taxane docetaxel, a semi-synthetic analogue of paclitaxel, with antineoplastic activity. Docetaxel binds specifically to the beta-tubulin subunit of the microtubule, stabilizing tubulin and inhibiting microtubule disassembly, which results in cell-cycle arrest at the G2/M phase, preventing cell proliferation. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and induces various mediators of the inflammatory response. Compared to docetaxel alone, the PNP formulation may enhance stability and improve delivery.

Cancer treatment using docetaxel by controlling peak plasma levels

Treatments of cancers involve a wide range of treatment. The current invention relates to chemotherapy of tumors using taxanes, in particular docetaxel. More in particular it relates to a method for the treatment of a cancer in a patient comprising orally administering an effective dose of docetaxel, whereby side effects are controlled by preventing peak plasma levels of docetaxel that induce said side effects, whilst maintaining an effective plasma level of docetaxel to eradicate tumor cells.
Owner:MODRA PHARMACEUTICALS B V

Docetaxel adiposome formulation, preparationmethod therefor, and use thereof

PCT designated stageWO2025185024A8Organic active ingredientsLiposomal deliveryDocetaxel-PNPBioavailability
Provided are a docetaxel adiposome formulation, a preparation method therefor, and use thereof. The docetaxel adiposome formulation comprises a monomolecular phospholipid membrane and docetaxel and a neutral lipid that are wrapped in the monomolecular phospholipid membrane. Targeted modification is further carried out on the surface of the docetaxel adiposome. The adiposome formulation has good bioavailability and safety, and the anti-cancer effect of the formulation is significantly superior to that of a clinically used docetaxel injection.
Owner:WECARELIFE BIOTECH CO LTD

Photodynamic balloon catheter system

ActiveCN115581847BBalloon catheterCoatingsEverolimusDocetaxel-PNP
The application discloses a kind of photodynamic balloon catheter systems, comprising: tube body, with opposite proximal end and distal end;Balloon, the balloon is fixed in the distal end portion of the tube body;Optical fiber assembly is inserted in the tube body, and with the light-emitting site extending to adjacent the balloon;The surface of the balloon is loaded with auxiliary material and photosensitizer in the form of coating;The photosensitizer can activate collagen and elastin under the wavelength of light 400-460nm to make them crosslink;The auxiliary material includes active drug and sustained-release material wrapped the active drug, the active drug is at least one of paclitaxel, rapamycin, zotarolimus, tacrolimus, everolimus, temsirolimus, zanolimus, biolimus, docetaxel, protein-bound paclitaxel and protein-bound dexamethasone;By the photodynamic balloon catheter system of the application can improve the utilization rate of active drug in intravascular administration.
Owner:HANGZHOU MATRIX MEDICAL TECH CO LTD

A docetaxel nano-prodrug targeting tumor cells and tumor stem cells and a preparation method and application thereof

PendingCN122145560AOrganic active ingredientsNanomedicineDocetaxel-PNPDocetaxel
The application discloses a docetaxel nano prodrug targeting tumor cells and tumor stem cells and a preparation method and application thereof. A docetaxel compound is synthesized through esterification and thiol-maleimide addition reaction, and a nano drug-loaded particle is prepared based on the docetaxel compound, so that the problems of low drug loading, poor targeting and tumor stem cell drug resistance in the prior art are solved, meanwhile, the nano drug-loaded particle can realize precise enrichment of the drug at a tumor site, improve the anti-tumor effect and reduce toxicity.
Owner:SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV +1